Loading...
Loading...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
bluebird bio, Inc.
BLUE announced that Marina Cavazzana, M.D.,
Ph.D., professor of hematology and director of the Department of
Biotherapy at Hospital Necker, University Paris Descartes and lead
investigator for the HGB-205 clinical study, presented a review of the
clinical study experience with lentiviral-based gene therapies for
beta-thalassemia at the 10th Annual Cooley's Anemia
Foundation Symposium in Chicago today.
Professor Cavazzana summarized results from HGB-205, an ongoing clinical
study using LentiGlobin® BB305 for the treatment of
beta-thalassemia major and severe sickle cell disease, which were
presented earlier this year at the Annual Congress of the European
Hematology Association. She also provided an update on subject 1003, a
patient with
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in